Related Experiment Video
Updated: May 29, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.6K
Hypoglycemia after bariatric surgery: Management updates
1Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, OH aniraiqbal93@gmail.com.
Cleveland Clinic Journal of Medicine
|February 3, 2025
Summary
Bariatric surgery can improve obesity-related conditions but may cause hypoglycemia. This article reviews current and emerging treatments for post-bariatric surgery hypoglycemia (PBH), a condition lacking approved medications.
Area of Science:
- Metabolic Surgery
- Endocrinology
- Gastroenterology
Background:
- Bariatric surgery offers significant health benefits for patients with obesity, including remission of type 2 diabetes and hypertension.
- A notable complication is post-bariatric surgery hypoglycemia (PBH), which can manifest months or years after the procedure.
- Currently, no specific medications are FDA-approved for managing PBH.
Purpose of the Study:
- To review the available and investigational treatment options for post-bariatric surgery hypoglycemia.
- To provide an overview of therapeutic strategies for this challenging complication.
Main Methods:
- Literature review of studies on PBH management.
- Analysis of current clinical guidelines and ongoing research.
Main Results:
- Discussion of pharmacologic and non-pharmacologic interventions.
- Highlighting emerging therapies under investigation for PBH.
Conclusions:
- Effective management of PBH requires a comprehensive approach.
- Further research is needed to develop approved and targeted therapies for PBH.
Related Concept Videos
01:15Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
01:14SBAR II: Application of SBAR
4.3K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.3K
01:06Oral Hypoglycemic Agents: Glinides
133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
01:16Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
01:15Diabetes: Management and Pharmacotherapy
232
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
232